Compare FENC & FOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FENC | FOF |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.8M | 375.8M |
| IPO Year | 2010 | N/A |
| Metric | FENC | FOF |
|---|---|---|
| Price | $12.49 | $11.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $17.40 | N/A |
| AVG Volume (30 Days) | ★ 180.6K | 70.4K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.07% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $67.26 | N/A |
| Revenue Next Year | $42.94 | N/A |
| P/E Ratio | $67.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $11.51 |
| 52 Week High | $13.25 | $15.04 |
| Indicator | FENC | FOF |
|---|---|---|
| Relative Strength Index (RSI) | 65.46 | 30.01 |
| Support Level | $9.58 | N/A |
| Resistance Level | $12.79 | $12.59 |
| Average True Range (ATR) | 0.86 | 0.24 |
| MACD | 0.19 | -0.04 |
| Stochastic Oscillator | 81.90 | 3.77 |
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. The Fund's investment objective is to achieve total return, consisting of high current income and potential capital appreciation.